Court Opinion

ID: 5123874
Source: CourtListenerOpinion
Date Created: 2021-11-06 02:00:54.089271+00
Date Added: 2024-06-11T08:22:36.453233
License: Public Domain

UNITED STATES DISTRICT COURT
                             FOR THE DISTRICT OF COLUMBIA

 NOVARTIS PHARMACEUTICALS
 CORPORATION,

                Plaintiff,

        v.
                                                          No. 21-cv-1479 (DLF)
 DIANA ESPINOSA,
 Acting Administrator, Health Resources and
 Services Administration, et al.,

                Defendants.

 UNITED THERAPEUTICS
 CORPORATION,

                Plaintiff,

        v.
                                                          No. 21-cv-1686 (DLF)
 DIANA ESPINOSA,
 Acting Administrator, Health Resources and
 Services Administration, et al.,

                Defendants.

                                 MEMORANDUM OPINION

       This case concerns conditions that plaintiffs Novartis Pharmaceuticals Corporation and

United Therapeutics Corporation have imposed on discounted drug purchases by certain safety-

net health care providers. The plaintiffs brought this suit to prevent threatened enforcement

actions by the Health Resources and Services Administration (HRSA). Before the Court are the

plaintiffs’ Motions for Summary Judgment, Dkt. 19 (Novartis); Dkt. 14 (United Therapeutics),

and the defendants’ Motions for Summary Judgment, Dkt. 13 (Novartis), Dkt. 16 (United
Therapeutics).1 For the reasons that follow, the Court will grant in part and deny in part the

plaintiffs’ motions for summary judgment and deny the defendants’ motions.

I.     BACKGROUND

       A. Statutory and Regulatory Framework

       In 1992, Congress enacted the Veterans Health Care Act (VHCA), Pub. L. No. 102-585,

106 Stat. 4943. Relevant here, the VHCA added Section 340B to the Public Health Service Act

(PHSA), Pub. L. No. 78-410, 58 Stat. 682 (1944), which created a program (the “340B

Program”) for certain healthcare providers (“covered entities”) to purchase certain drugs from

drug manufacturers at reduced prices. See § 602, 106 Stat. at 4967–71 (codified at 42 U.S.C. §

256b). Drug manufacturers can participate in the 340B Program by entering into voluntary

agreements with the Secretary of Health and Human Services “under which the amount required

to be paid . . . to the manufacturer for covered outpatient drugs . . . purchased by a covered entity

. . . does not exceed an amount equal to the average manufacturer price . . . reduced by the

[statutory] rebate percentage.” 42 U.S.C. § 256b(a)(1); see also Astra USA, Inc. v. Santa Clara

Cnty., Cal., 563 U.S. 110, 113 (2011) (“Section 340B . . . imposes ceilings on prices drug

manufacturers may charge for medications sold to specified health-care facilities.” (internal

citations omitted)). The statutory scheme starts with a carrot. The 340B Program allows the

drugs of participating manufacturers to be eligible for reimbursement under Medicaid and

Medicare Part B. See 42 U.S.C. § 1396r–8(a). Because covered entities are mostly “providers of

safety-net services to the poor,” Astra, 563 U.S. at 113, this price cap helps contain costs for low-

1
  The Court held a joint motions hearing in these related cases after the parties in Novartis agreed
to consolidate a hearing on Novartis’s motion for a preliminary injunction with a hearing on the
merits in both cases. See Minute Order of July 15, 2021. For clarity, the Court will note the
accompanying case name in a parenthetical following the citation of each docket entry.
                                                  2
income providers, see AstraZeneca Pharmaceuticals LP v. Becerra, No. 21-cv-27-LPS, 2021

WL 2458063, at *1 (D. Del. June 16, 2021); see also 42 U.S.C. § 256b(a)(4) (listing fifteen

classes of covered entities).

       The benefits of the 340B Program do not come without strings attached. Covered entities

cannot receive “duplicate discounts” on drugs purchased at 340B prices. 42 U.S.C.

§ 256b(a)(5)(A). They also “shall not resell or otherwise transfer the drug to a person who is not

a patient of the entity.” Id. § 256b(a)(5)(B). To police compliance, manufacturers and the

Secretary are permitted “to audit at the Secretary’s or the manufacturer’s expense the records of

the [covered] entit[ies].” Id. § 256b(a)(5)(C). Failure to comply with these requirements can

lead to sanctions for covered entities. See id. § 256b(a)(5)(D).

       Since 1994, when the 340B program was created, HRSA has issued several nonbinding

interpretive guidance documents that set forth the parameters of the program. In 1994, HRSA

explained that covered entities could “use a purchasing agent without forfeiting its right to

section 340B drug discounts,” regardless of whether the agent only “negotiates the drug

purchasing contracts . . . or actually receives drug shipments for distribution” without falling

afoul of the drug diversion prohibition. Final Notice Regarding Section 602 of the Veterans

Health Care Act of 1992 Entity Guidelines, 59 Fed. Reg. 25,110, 25,113 (1994). HRSA also

took positions on what manufacturers could not do. They could “not single out covered entities

from their other customers for restrictive conditions that would undermine the statutory

objective” or “place limitations on the transactions . . . which would have the effect of

discouraging entities from participating in the discount program.” Id. And manufacturers could

“not condition the offer of statutory discounts upon an entity’s assurance of compliance with

section 340B provisions.” Id.

                                                 3
       In 1996, HRSA considered the question of how covered entities could distribute

discounted drugs to their patients. See Notice Regarding Section 602 of the Veterans Health

Care Act of 1992; Contract Pharmacy Services, 61 Fed. Reg. 43,549 (1996). HRSA recognized

that Section 340B “[wa]s silent as to permissible drug distribution systems.” Id. at 43,549. It

took the position that covered entities could contract with outside pharmacies to (1) receive

shipment of the discounted drugs from the manufacturer, (2) distribute those drugs to the covered

entities’ patients, and (3) place 340B-priced orders to refill their inventories. See id. at 43,549–

50, 43,552. The reason for this practice, HRSA explained, was that only approximately four

percent of covered entities had in-house pharmacies. See id. at 43,550. HRSA stated that “[i]t

would defeat the purpose of the 340B program if these covered entities could not use their

affiliated pharmacies in order to participate in the 340B program.” Id. “Otherwise, [the covered

entities] would be faced with the untenable dilemma of having either to expend precious

resources to develop their own in-house pharmacies (which for many would be impossible) or

forego participation in the program altogether.” Id. HRSA considered contract pharmacies in

this arrangement to be “act[ing] as . . . agent[s] of the covered entit[ies].” Id.

       HRSA’s interpretation of Section 340B also included obligations. Manufacturers were

obligated “to sell the drug at the discounted price” to covered entities that purchase drugs in this

fashion. Id. at 43,549; see also id. at 43,555 (“Under section 340B, we believe that if a covered

entity using contract pharmacy services requests to purchase a covered drug from a participating

manufacturer, the statute directs the manufacturer to sell the drug at the discounted price.”).

Covered entities also remained under “the statutory prohibition on drug diversion” when

employing contract pharmacies. Id. at 43,550. To that end, contract pharmacies were required to

“provide the covered entity with reports” and “establish and maintain a tracking system suitable

                                                   4
to prevent diversion of section 340B discounted drugs to individuals who are not patients of the

covered entity.” Id. at 43,555. HRSA also stated that Section 340B contained a “limitation of

one pharmacy contractor per entity.” Id.

        In 2007, HRSA provided notice that it was considering changes to the general operation

of the 340B Program. See Notice Regarding 340B Drug Pricing Program—Contract Pharmacy

Services, 72 Fed. Reg. 1540 (2007). After seeing success in an early-2000s pilot program that

allowed “[t]he use of multiple contract pharmacy service sites” and “the utilization of a contract

pharmacy to supplement in-house pharmacy services,” the agency “propose[d] new guidelines

that would allow covered entities to utilize multiple contract pharmacy service sites” and allow

covered entities with in-house pharmacies to utilize contract pharmacies as well. Id. at 1540.

        HRSA finalized these changes in 2010. See Notice Regarding 340B Drug Pricing

Program—Contract Pharmacy Services, 75 Fed. Reg. 10,272 (2010). The 2010 guidelines

maintained the above parameters but also shifted from allowing “a single point for pharmacy

services, either an in-house pharmacy or an individual contract pharmacy” to permit covered

entities “to use multiple pharmacy arrangements as long as they comply with guidelines

developed to help ensure against diversion and duplicate discounts.” Id. at 10,272–73. HRSA

explained that this change would help “covered entities . . . more effectively utilize the 340B

program and create wider patient access by having more inclusive arrangements in their

communities which would benefit covered entities, pharmacies and patients served.” Id. at

10,273. This comment responded to concerns that covered entities had expressed about “patients

[who] . . . face[d] transportation barriers or other obstacles that limit[ed] their ability to fill their

prescriptions.” Id.

                                                    5
       Although the agency did not proceed through notice-and-comment rulemaking, it

nonetheless responded to comments on this proposal. First, HRSA stated that its “guidance

neither impose[d] additional burdens upon manufacturers, nor” did it “create[] any new rights for

covered entities under the law.” Id. It agreed that “independent audits can play an important

role in ensuring program integrity,” and it revised the guidelines “to state that the covered

entit[ies] must have sufficient information to meet [their] obligation[s] of ensuring ongoing

compliance” with the 340B Program. Id. at 10,274. Nonetheless, the agency “d[id] not agree

that utilization of more than one contract pharmacy create[d] an automatic cause to suspect

diversion.” Id. Nor did it impose any new inventory or record control mechanisms. See id. at

10,275.

       But the agency did establish some additional parameters. HRSA required covered

entities to “have a written contract in place between itself and a specified pharmacy.” Id. at

10,277. And it made covered entities responsible for “purchas[ing] the drug, maintain[ing] title

to the drug and assum[ing] responsibility for establishing its price.” Id. For distribution

purposes, covered entities could purchase and pay for the drug, but the agency required the

manufacturer to “ship[] the drug directly to the contract pharmacy.” Id.

       Around the same time in 2010, Congress added a stick to the 340B program by giving the

Secretary the authority to seek civil monetary penalties from manufacturers “that knowingly and

intentionally charge[] a covered entity a price for purchase of a drug that exceeds the maximum

applicable [discounted] price.” Patient Protection and Affordable Care Act, Pub. L. No. 111-

148, § 7102(a), 124 Stat. 119, 825 (2010) (codified at 42 U.S.C. § 256b(d)(1)(vi)). Congress

also amended Section 340B(a)(1) to require manufacturers to “offer each covered entity covered

drugs for purchase at or below the applicable ceiling price if such drug is made available to any

                                                 6
other purchaser at any price.” Id. § 7102(b)(1), 124 Stat. at 827 (also known as the “Shall Offer”

provision).

        B. Procedural History

        Concerned about the potential for increased fraud, duplicate discounts, and drug

diversion, Novartis and United Therapeutics notified HRSA of their intention to change their

340B drug policies as a result of HRSA’s 2010 guidelines. See Verified Compl. ¶¶ 32–39, 49,

Dkt. 1 (Novartis); Compl. ¶¶ 53–72, 74, Dkt. 1 (United Therapeutics). Novartis’s new policy

honors (1) all covered pharmacy arrangements in which “the contract pharmacy is located within

a 40-mile radius of the covered entity” and (2) all contract pharmacies of “[f]ederal grantee

covered entities.” Novartis Compl. ¶¶ 42–43. The company also offers exemptions “if a

hospital covered entity brings a special circumstance to Novartis’s attention.” Id. ¶ 44. If

Novartis receives an order from a covered entity ineligible under these policies, it does not

convert the order to a full-price order but rather declines to fill the order. Id. ¶ 48.

        United Therapeutics takes a slightly different approach. It honors only purchases

directed to those contract pharmacies that were “used by the related covered entity to make a

valid 340B purchase of [its] drug[s] during the first three quarters of the 2020 calendar year.”

United Therapeutics Compl. ¶ 75. And covered entities that have had neither a contract

pharmacy during that period nor an in-house pharmacy are permitted to designate a single

contract pharmacy. Id. ¶ 76. United Therapeutics also requires all covered entities using

contract pharmacies “to regularly provide claims data to [United Therapeutics] via a third-party

platform, among other things, allowing [the manufacturer] to confirm that contract pharmacies

are genuinely acting on behalf of a covered entity.” Id. ¶ 77.

                                                   7
       In response to these policy changes by drug manufacturers, the General Counsel of HHS

issued an Advisory Opinion in December 2020. See A.R. 6832–36, Dkt. 25 (Novartis). The

Department “conclude[d] that to the extent contract pharmacies [we]re acting as agents of a

covered entity, a drug manufacturer in the 340B Program [wa]s obligated to deliver its covered

outpatient drugs to those contract pharmacies and to charge the covered entity no more than the

340B ceiling price for those drugs.” Id. at 6832. The agency found that Section 340B’s

“purchased by” language was abundantly clear. Id. at 6833. This language provides that “[t]he

Secretary shall enter into an agreement with each manufacturer of covered outpatient drugs

under which the amount required to be paid . . . to the manufacturer for covered outpatient drugs

. . . purchased by a covered entity . . . does not exceed [the ceiling price].” Id. In the

Department’s view, “[i]t is difficult to envision a less ambiguous phrase.” Id.; see id. at 6834

(stating that “the situs of delivery, be it the lunar surface, low-earth orbit, or a neighborhood

pharmacy, is irrelevant”). The Advisory Opinion further stated that the agency’s view was also

supported by the purpose and history of the program and the Department’s longstanding

interpretation of the statute. See id. at 6834–36. Finally, the Department rejected the drug

manufacturers’ arguments that their actions were necessary to prevent duplicate discounting and

drug diversion on the grounds that the statute provided only two mechanisms for dispute

resolution, neither of which permitted manufacturers to impose the restrictions on 340B

purchasers. See id. at 6836–38.

       This opinion was quickly challenged, and it did not withstand judicial scrutiny. In June

2021, the U.S. District Court for the District of Delaware held that “the Opinion [wa]s legally

flawed” because it “wrongly determine[d] that purportedly unambiguous statutory language

mandate[d] its conclusion regarding covered entities’ permissible use of an unlimited number of

                                                  8
contract pharmacies.” AstraZeneca, 2021 WL 2458063, at *8. Judge Stark first explained “that

the government’s position on drug manufacturers’ obligations with respect to participation in the

340B Program ha[d] not remained constant but ha[d], instead, materially shifted.” Id. at *6

(emphasis in original). Over twenty-five years, “the government ha[d] dramatically expanded

how covered entities may purchase 340B drugs,” and this expansion of covered entities’ rights

had in turn expanded manufacturers’ duties. Id. at *7.

       On the merits, Judge Stark found that “[t]he statute [wa]s silent as to the role that contract

pharmacies may play in connection with covered entities’ purchases of 340B drugs” and that this

was “a strong indication that the statute does not compel any particular outcome with respect to

covered entities’ use of pharmacies.” Id. at *9. He explained that the “purchased by” language

of Section 340B(a)(1) directly imposed an obligation only on the Secretary “and only indirectly

impose[d] obligations on manufacturers” without speaking “to the amount of . . . drugs

purchased or the model by which the drugs are distributed.” Id. The government’s position had

effectively added a requirement to the 340B statute—i.e., “pharmaceutical manufacturers are

required to deliver 340B drugs to an unlimited number of contract pharmacies”—that is not

contained in the statute and therefore not compelled by it. Id. at *10. And because the

Department “wrongly believe[d] that [its] interpretation [wa]s compelled by Congress,” id. at

*11 (quoting Peter Pan Bus Lines, Inc. v. Fed. Motor Carrier Safety Admin., 471 F.3d 1350,

1354 (D.C. Cir. 2006)), the Opinion was unlawful, id. at *8. The Department responded by

withdrawing the Opinion. See Notice of Withdrawal (June 18, 2021), available at

https://www.hhs.gov/sites/default/files/notice-of-withdrawal-of-ao-20-06-6-18-21.pdf (last

visited Nov. 5, 2021).

                                                 9
       In the meantime, the agency had begun an investigation of Novartis’s and United

Therapeutics’s 340B practices. On May 17, 2021, HRSA sent letters to the companies

concluding that their “actions have resulted in overcharges and are in direct violation of the 340B

statute.” Novartis Compl. Ex. 2, at 1, Dkt. 1-2 (Violation Letter); United Therapeutics Compl.

Ex. 2, at 1, Dkt. 1-2 (Violation Letter). HRSA explained that the “Shall Offer” language of

Section 340B(a)(1) imposed a “requirement” that was “not qualified, restricted, or dependent on

how the covered entity chooses to distribute the covered outpatient drugs.” Novartis Violation

Letter at 1; United Therapeutics Violation Letter at 1. According to HRSA, the statute did not

“grant[] manufacturer[s] the right to place conditions on [their] fulfillment of [their] statutory

obligation to offer 340B pricing on covered outpatient drugs purchased by covered entities.”

Novartis Violation Letter at 1; United Therapeutics Violation Letter at 1. And manufacturers

were “expected to provide the same opportunity for 340B covered entities and non-340B [drug]

purchasers to purchase covered outpatient drugs.” Novartis Violation Letter at 1; United

Therapeutics Violation Letter at 1. The agency argued that it had made this requirement “plain,

consistently since the” 1996 guidelines, “that the 340B statute require[d] manufacturers to honor

such purchases regardless of the dispensing mechanism.” Novartis Violation Letter at 1; United

Therapeutics Violation Letter at 1. Rejecting the companies’ anti-fraud arguments, HRSA noted

that the statute provides mechanisms for addressing drug manufacturers’ concerns about the

potential for fraud, diversion, and duplicate discounting, namely an audit of covered entities and

an administrative dispute resolution process. Novartis Violation Letter at 2; United Therapeutics

Violation Letter at 2. It did not, however, “permit a manufacturer to impose industry-wide,

universal restrictions.” Id. The letters closed by threatening enforcement action if the companies

did not comply. Id.

                                                 10
       Both companies responded by filing these suits under the Administrative Procedure Act

(APA) seeking, among other things, declaratory relief that the agency’s position is unlawful,

vacatur of the Violation Letters, and injunctive relief barring enforcement actions. See Novartis

Compl. 25; United Therapeutics Compl. 51. On July 15, 2021, with the consent of the parties,

the Court consolidated resolution of Novartis’s preliminary injunction motion with the cross-

motions for summary judgment filed by the parties in both cases. See Minute Order of July 15,

2021. These motions are now ripe for decision.

II.    LEGAL STANDARDS

       A court grants summary judgment if the moving party “shows that there is no genuine

dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed.

R. Civ. P. 56(a); see also Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 247–48 (1986). A

“material” fact is one with potential to change the substantive outcome of the litigation. See id.

at 248; Holcomb v. Powell, 433 F.3d 889, 895 (D.C. Cir. 2006). A dispute is “genuine” if a

reasonable jury could determine that the evidence warrants a verdict for the nonmoving

party. See Liberty Lobby, 477 U.S. at 248; Holcomb, 433 F.3d at 895.

       In an Administrative Procedure Act case, summary judgment “serves as the mechanism

for deciding, as a matter of law, whether the agency action is supported by the administrative

record and otherwise consistent with the APA standard of review.” Sierra Club v. Mainella, 459

F. Supp. 2d 76, 90 (D.D.C. 2006). The Court will “hold unlawful and set aside” agency action

that is “arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law,” 5

U.S.C. § 706(2)(A), “in excess of statutory jurisdiction, authority, or limitations, or short of

statutory right,” id. § 706(2)(C), or “unsupported by substantial evidence,” id. § 706(2)(E).

                                                 11
III.   ANALYSIS

       The question properly before the Court is whether the Violation Letters—which conclude

that the manufacturers’ conditions “are in direct violation of the 340B statute,” Novartis

Violation Letter at 1; United Therapeutics Violation Letter at 1—are unlawful.

       In assessing this question, the Violation Letters are not entitled to Chevron deference.

That degree of deference is appropriate only when an agency employs “‘delegated legislative

power’ from Congress,” Guedes v. Bureau of Alcohol, Tobacco, Firearms & Explosives, 920

F.3d 1, 17–18 (D.C. Cir. 2019) (quoting Am. Mining Cong. v. Mine Safety & Health Admin, 995

F.2d 1106, 1109 (D.C. Cir. 1993)), and intends to act with “the ‘force and effect of law,’” id. at

18 (quoting Encino Motorcars, LLC v. Navarro, 136 S. Ct. 2117, 2122 (2016)). Although

Congress granted HRSA the power to bring enforcement actions, see 42 U.S.C. § 256b(d)(1)(B),

the Violation Letters at issue here do not have the force of law. These enforcement notices also

do not have general applicability but instead target Novartis and United Technologies because of

their particular 340B drug policies. See Kaufman v. Nielsen, 896 F.3d 475, 484–85 (D.C. Cir.

2018). Finally, HRSA has waived Chevron deference by expressly claiming Skidmore deference

instead. See Defs.’ Mem. of P. & A. in Opp’n to Pl.’s Mot. for Prelim. Inj. at 39, Dkt. 13-1; see

also HollyFrontier Cheyenne Refining, LLC v. Renewable Fuels Ass’n, 141 S. Ct. 2172, 2180

(2021) (declining to address Chevron when the government has not invoked it). Accordingly,

the Court will “accept the agency’s interpretation” of Section 340B set forth in the Violation

Letters “only if it is the best reading of the statute,” Guedes, 920 F.3d at 17, and it will give the

agency’s interpretation deference only proportionate to its “power to persuade,” Skidmore v.

Swift & Co., 323 U.S. 134, 140 (1944).

                                                  12
       A. The Statute’s Text

       With that framework in mind, this Court starts, as always, with the text. Ross v. Blake,

578 U.S. 632, 638 (2016). The relevant text from Section 340B is as follows:

       The Secretary shall enter into an agreement with each manufacturer of covered
       outpatient drugs under which the amount required to be paid . . . to
       the manufacturer for covered outpatient drugs . . . purchased by a covered
       entity . . . does not exceed an amount equal to the average manufacturer price for
       the drug . . . in the preceding calendar quarter, reduced by the rebate
       percentage described in paragraph (2). Each such agreement shall require that
       the manufacturer furnish the Secretary with reports, on a quarterly basis, of the
       price for each covered outpatient drug subject to the agreement that, according to
       the manufacturer, represents the maximum price that covered entities may
       permissibly be required to pay for the drug (referred to in this section as the “ceiling
       price”), and shall require that the manufacturer offer each covered entity covered
       outpatient drugs for purchase at or below the applicable ceiling price if such drug
       is made available to any other purchaser at any price.

42 U.S.C. § 256(a)(1). As HRSA has long recognized, “[t]he statute is silent as to permissible

drug distribution systems.” 61 Fed. Reg. at 43,549. It is also silent as to what distribution

requests manufacturers must accept. See AstraZeneca Pharms., 2021 WL 2458063, at *9. The

statute’s silence on these questions suggests “that the statute does not compel any particular

outcome with respect to covered entities’ use of pharmacies.” Id.

       HRSA resists this reading of the statute, finding a clear statutory directive in Section

340B’s “Shall Offer” provision which requires manufacturers to offer their drugs to covered

entities at the discounted price if they offer them to other purchasers. See Defs.’ Novartis Mem.

at 23; Defs.’ United Therapeutics Mem. at 18–20 (citing 42 U.S.C. § 256b(a)(1)). HRSA’s

interpretation, however, stretches the “Shall Offer” provision beyond its plain meaning. An

“offer” is defined as “[t]he act or instance of presenting something for acceptance.” Offer (def.

1), Black’s Law Dictionary (11th ed. 2019). Here, even with the added conditions imposed by

the drug manufacturers’ new policies, both manufacturers continue to present their drugs to

                                                 13
covered entities, as the “Shall Offer” provision requires.2 Novartis’s policy offers discounted

drugs to covered entities that provide drugs through in-house pharmacies, through any contract

pharmacy within a forty-mile radius of the covered entity, through any contract pharmacy of a

federal grantee, and through any contract pharmacy specially exempted from this policy. See

Novartis Compl. ¶¶ 42–44. United Therapeutics offers discounted drugs to covered entities

through all contract pharmacies used in the first three quarters of 2020 and through a single

contract pharmacy for covered entities that did not have a contract pharmacy in that time, so long

as they provide claims data to the company. See United Therapeutics Compl. ¶¶ 75–77.

Although the manufacturers’ offers are subject to more conditions than they previously were,

they are still meaningful, bona fide offers, notwithstanding HRSA’s argument to the contrary,

see Defs.’ Mem. of P. & A. in Opp’n to Pl.’s Mot. for Summ. J. at 26, Dkt. 16-1 (United

Therapeutics). A cursory review of the plaintiffs’ new conditions shows that covered entities

now have far more opportunities to purchase drugs at 340B prices than they did when HRSA

limited covered entities to one contract pharmacy.

       To be sure, Section 340B does not expressly grant manufacturers the authority “to place

conditions on [their] fulfillment of [their] statutory obligations.” Novartis Violation Letter at 1;

United Therapeutics Violation Letter at 1. But neither does the “Shall Offer” provision nor any

other language in Section 340B prohibit manufacturers from placing any conditions on covered

2
  The government is incorrect that the record contains evidence of 340B violations. Although the
record contains evidence that some covered entities were refused 340B pricing, see, e.g.,
Novartis A.R. 1468, 1474, 2592; A.R. 5766, 5769, Dkt. 23 (United Therapeutics), it does not
show that any of those entities were not offered 340B pricing upon compliance with the
manufacturers’ policies. That is what HRSA would need to show for the record to establish a
340B violation. The Court will not consider the government’s recently filed Notice of Filing
Corrected Document from the Administrative Record, Dkt. 26 (United Therapeutics), because it
is untimely. See Pl.’s Response, Dkt. 28 (United Therapeutics).

                                                 14
entities. Indeed, HRSA itself has long recognized that manufacturers are allowed to “include

provisions” in their contracts with covered entities “that address customary business practice,

request standard information, or include other appropriate contract provisions.” 59 Fed. Reg. at

25,114. The additional conditions added to the manufacturers’ new policies certainly extend

beyond those that the manufacturers previously imposed. But HRSA does not adequately

explain why the plain language of the statute allows manufacturers to impose only the conditions

they previously imposed.

       As additional justification for its position, HRSA contends that the “Shall Offer”

provision in Section 340B is an anti-discrimination provision that forbids manufacturers from

offering drugs to covered entities on different terms or with different requirements than they

offer to commercial entities. See Defs.’ Novartis Mem. at 22–24; Defs.’ United Therapeutics

Mem. at 19–21. It is true that HRSA’s guidance documents have long taken the position that

Section 340B prohibits discrimination. See, e.g., 59 Fed. Reg. at 25,113 (forbidding

manufacturers from “singl[ing] out covered entities from their other customers for restrictive

conditions” and from requiring covered entities’ “assurance[s] of compliance with section 340B

provisions”). But on its face, the “Shall Offer” provision—which requires only that

manufacturers “shall . . . offer each covered entity covered drugs” at a discounted rate “if such

drug is made available to any other purchaser at any price,” 42 U.S.C. § 256b(a)(1)—provides no

statutory hook for HRSA’s guidance. And it would be strange to treat Section 340B’s “Shall

Offer” language as incorporating a broad anti-discrimination rule when Congress knows full well

how to forbid discrimination. In another healthcare provision, for example, Congress used the

word “discriminate” to ban discrimination. See 42 U.S.C. § 300gg-5(a) (“A group health plan

and a health insurance issuer offering group or individual health insurance coverage shall not

                                                15
discriminate with respect to participation under the plan or coverage against any health care

provider who is acting within the scope of that provider’s license or certification under

applicable State law.”). Congress also has used similarly clear language in other contexts to

prohibit various types of discrimination. See, e.g., id. § 2000e-2(a) (prohibiting employment

actions on the basis of race, color, religion, sex, or national origin). Neither the “Shall Offer”

provision nor any other in Section 304B contains such clear language that forbids drug

manufactures from imposing any additional conditions—no matter how minor—on covered

entities that purchase drugs at 340B discount prices.

       Lacking a clear textual hook for its interpretation of Section 340B, HRSA invokes the

statute’s purpose to defend its Violation Letters. See, e.g., Defs.’ United Therapeutics Mem. at

25–27. The purpose of Section 340B is clear—it provides discounts on drugs to certain kinds of

healthcare facilities. To that end, the more opportunities that covered entities have to purchase

discounted drugs, the more money they can save. But “no legislation pursues its purposes at all

costs.” CTS Corp. v. Waldburger, 573 U.S. 1, 12 (2014) (quoting Rodriguez v. United States,

480 U.S. 522, 525–26 (1987) (per curiam)). And Section 340B is no exception. The statute

clearly prohibits covered entities from receiving duplicate discounts on drugs, and it directs the

Secretary to determine an enforcement mechanism. 42 U.S.C. § 256b(a)(5)(A). It also prohibits

covered entities from reselling or transferring discounted drugs to anyone who is not a patient of

the covered entity.3 Id. § 256b(a)(5)(B). To effectuate these anti-fraud provisions, the statute

3
 United Therapeutics’ argument that deliveries to covered pharmacies are a transfer in violation
of this provision, see Mem. in Supp. of Pl.’s Mot. for Summ. J. at 28–31, Dkt. 14-1 (United
Therapeutics), is unpersuasive. First, the reference to “patients” in the statutes suggests that the
concern is transfers to end users of the drugs, not possible intermediaries. Second, this position
would suggest that the use of any courier, including the U.S. Postal Service, UPS, or FedEx, for
drug distribution would be impermissible. Finally, under this reading, the plaintiffs’ current
policies would be problematic because they allow some contract pharmacy use.

                                                 16
requires covered entities to allow audits by either the Secretary or the manufacturer, and it

subjects covered entities to sanctions for noncompliance. Id. § 256b(a)(5)(C)–(D). This

structure suggests that Congress did not intend Section 340B’s purpose to be pursued at all

costs.4

          Even so, HRSA’s Violation Letters gesture toward this statutory structure as further

justification for its interpretation of Section 340B. See Novartis Violation Letter at 2; United

Therapeutics Violation Letter at 2 (explaining that, because the 340B statute has mechanism to

address fraud, it “does not permit a manufacturer to impose industry-wide, universal

restrictions”). And certainly where, as here, the statutory text is silent on an issue of statutory

interpretation, structure and purpose inform the meaning of a statute. See Eagle Pharms., Inc. v.

Azar, 952 F.3d 323, 332 (D.C. Cir. 2020). Although HRSA’s Violation Letters mention 340B’s

statutory structure, the agency invokes this justification only in response to the manufacturers’

anti-fraud rationales, and it does not develop the structural argument in its briefs as a basis for its

interpretation of Section 340B.5 See Novartis Violation Letter at 2; United Therapeutics

Violation Letter at 2. It instead asserts, without any analysis, that the built-in audit and ADR

4
  The Court does not find the reasoning of Eli Lilly & Co. v. U.S. Dep’t of Health & Human
Servs., No. 21-cv-81, 2021 WL 5039566 (S.D. Ind. Oct. 29, 2021), persuasive. That court
interpreted Section 340B’s “Shall Offer” language in light of the statute’s purpose and concluded
that it precludes manufacturers from conditioning their offers. See id. at *18–19. For the
reasons stated in this opinion, see infra 16–18, this Court rejects HRSA’s interpretation that
Section 340B’s plain language, purpose, and structure preclude the manufacturers from imposing
any new conditions, see Defs.’ United Therapeutics Mem. at 41–42; Defs.’ Novartis Reply at
14–15.
5
  In its briefs, HRSA raised the structure point to explain why its actions were not arbitrary and
capricious. See Defs.’ United Therapeutics Mem. at 41–42; Defs.’ Novartis Reply at 14–15. But
it did not argue that the structure shows that the agency’s position is in accordance with the
statute. And in Novartis, HRSA raised the argument only in its reply brief. See Baloch v.
Norton, 517 F. Supp. 2d 345, 348 n.2 (D.D.C. 2007) (courts are not required to consider new
arguments in a reply).

                                                  17
mechanisms preclude drug manufacturers from imposing any additional conditions to police

fraud in connection with 340B purchases. See Defs.’ Reply at 14–15, Dkt. 23 (Novartis); Defs.’

United Therapeutics Mem. at 41–42; Defs.’ Reply at 18, Dkt. 22 (United Therapeutics). HRSA

makes no attempt to explain why Section 340B’s structure prohibits any additional conditions,

no matter how minor, and for the reasons stated above, it cannot. HRSA also does not explain

why Section 340B’s structure prohibits the specific conditions that Novartis and United

Therapeutics have imposed under their new 340B policies. For its part, United Therapeutics

convincingly argues that the claims data conditions that it has added to its new 340B policy will

enable it to better utilize the anti-fraud audit and ADR procedures that Congress established for

manufacturers in Section 340B. See United Therapeutics Mem. at 37–39. Because the parties

have not adequately argued their respective positions on Section 340B’s structure, the Court

declines to decide whether Section 340B permits or prohibits any of the specific conditions at

issue here.6

       Finally, HRSA’s guidance documents do not provide further support for the agency’s

interpretation of Section 340B. First, even though the agency asserts that its guidance documents

reflect the agency’s “longstanding interpretation of the statute,” Defs.’ Novartis Mem. at 2, 9,

22–25; Defs.’ United Therapeutics Mem. at 2, 7, 28–29, its position has in fact shifted over time.

In 1996, when the government first established guidance for covered entities’ use of contract

pharmacy services, HRSA set a “limitation of one pharmacy contractor per entity.” 61 Fed. Reg.

at 43,555. In 2010, however, the agency changed its position by permitting covered entities “to

use multiple pharmacy arrangements.” 75 Fed. Reg. at 10,273. HRSA recognized then that it

6
  The Court cannot decide those questions without appropriate briefing because they likely turn,
for example, on the mechanics of how audits work and the degree to which the manufacturer
conditions at issue here undermine the operation of the 340B program.

                                                18
was changing its position from its 1996 guidelines, see id. at 10,272–73, but it paradoxically

stated that its new “guidance neither impose[d] additional burdens upon manufacturers, nor

create[d] any new rights for covered entities under the law,” id. at 10,273. This is incorrect. By

changing its position on “what covered entities may do,” the agency necessarily changed its

position on “what drug manufacturers must do.” AstraZeneca, 2021 WL 2458063, at *7.

Second, the agency’s shifting guidance illustrates that is it attempting to fill a gap in this statute,

and this the agency cannot do. Any such gap-filling must be accomplished by a legislative rather

than an interpretive rule. See Nat’l Mining Ass’n v. Kempthorne, 512 F.3d 702, 709 (D.C. Cir.

2008); see also Am. Mining Cong., 995 F.2d at 1109–12 (explaining the distinction between

legislative rules and interpretive rules). But HRSA lacks the authority to issue a legislative rule.

See Defs.’ Notice of Suppl. Authority at 3 n.1, Dkt. 29 (Novartis) (“HRSA [has] acknowledged

that it lacks an explicit grant of comprehensive rulemaking authority.”); see also Pharm.

Research & Mfrs. of Am. v. U.S. Dep’t of Health & Human Servs., 43 F. Supp. 3d 28, 46 (D.D.C.

2014) (finding the same for an Orphan Drug Rule in the context of the 340B Program). As such,

HRSA cannot circumvent this requirement by calling its gap-filling “interpretive guidance.”7

7
  The agency also leans on legislative history to support its interpretation. See Defs.’ Novartis
Mem. at 25–26; Defs.’ United Therapeutics Mem. at 27–28. In general, citation to legislative
history is problematic. See generally Antonin Scalia, A Matter of Interpretation 36 (1997)
(describing the use of legislative history to be like picking out one’s friends at a party). And in
any event, there is insufficient evidence to support HRSA’s argument, see Defs.’ Novartis Mem.
at 25 (discussing S. Rep. No. 102-259, at 1–2 (1992)), that the Senate’s removal of a provision in
Section 340B that would have required covered entities to use in-house pharmacies shows that
the statute requires manufacturers to accept all outside pharmacy arrangements, cf.
Bridgestone/Firestone, Inc. v. Pension Benefit Guar. Corp., 892 F.2d 105, 110 (D.C. Cir. 1989)
(finding that the absence of specific language that Congress considered in the final statute did not
speak to whether Congress rejected that scheme).
                                                  19
       B. Remedy

       Pursuant to 28 U.S.C. § 2201, the Court will declare that the plaintiffs’ policies do not

violate Section 340B under the positions advanced in the Violation Letters and developed in this

litigation. The plain language, purpose, and structure of the statute do not prohibit the

manufacturers from imposing any conditions on their offers of 340B-priced drugs to covered

entities. Therefore, the Court will set aside those letters. See 5 U.S.C. § 706(2). Based on the

current record, however, the Court will not go as far as the plaintiffs have requested and declare

that their policies are permissible under Section 340B. Nor will the Court issue any injunctive

relief at this time. In granting this narrow relief, the Court expresses no view as to whether any

other legal theory—such as one based on the structure of Section 340B—rules out the plaintiffs’

specific conditions.

                                  *              *               *

       The parties in these related cases have raised legitimate concerns about the operation of

the 340B program. The drug manufacturers have highlighted credible evidence that HRSA’s

recent guidelines permitting covered entities to use multiple pharmacies to distribute discounted

drugs to patients have increased the potential for fraud in the 340B program. See Novartis

Compl. ¶¶ 38, 72; United Therapeutics Compl. ¶¶ 5, 8, 53, 58, 60, 63, 65–66. At the same time,

HRSA has expressed legitimate concerns about the degree to which the manufacturers’ new

conditions have made it difficult for covered entities to obtain certain drugs at discounted prices.

See, e.g., Novartis A.R. 1468, 1474, 2592, 3136, 5256, 5744, 5748; United Therapeutics A.R.

5766, 5769.

       But Section 340B does not say as much as any of the parties in these two cases argue.

The Violation Letters contain legal reasoning that rests upon an erroneous reading of Section

340B. The statute’s plain language, purpose, and structure do not prohibit drug manufacturers
                                                 20
from attaching any conditions to the sales of covered drugs through contract pharmacies. Nor do

they permit all conditions. Accordingly, any future enforcement action must rest on a new

statutory provision, a new legislative rule, or a well-developed legal theory that Section 340B

precludes the specific conditions at issue here.

                                         CONCLUSION

       For the above stated reasons, the plaintiffs’ Motions for Summary Judgment are granted

in part and denied in part, and the defendants’ Motion for Summary Judgment is denied. An

order consistent with this decision accompanies this memorandum opinion.

                                                            ________________________
                                                            DABNEY L. FRIEDRICH
                                                            United States District Judge
November 5, 2021

                                                   21